**Acetylcholinesterase Inhibitor Brief: References**

1\. Fricker RD, Reardon E, Spektor DM, et al. A Review of the Scientific
Literature as It Pertains to Gulf War Illnesses. Volume 12: Pesticide
Use During the Gulf War: A Survey of Gulf War Veterans. Santa Monica,
CA: RAND, MR-1018/12-OSD; 2000.

2\. Golomb BA. Illness in Persian Gulf War veterans: Evidence for a
causal role for acetylcholinesterase inhibitors (pyridostigmine bromide,
pesticides, and nerve agent). Submitted.

3\. Nisenbaum R, Barrett DH, Reyes M, Reeves WC. Deployment stressors
and a chronic multisymptom illness among Gulf War veterans. *J Nerv Ment
Dis*. 2000;188:259-66.

4\. Unwin C, Blatchley N, Coker W, et al. Health of UK servicemen who
served in the Persian Gulf war. *Lancet*. 1999;353:169-178.

5\. Golomb BA. A Review of the Scientific Literature as it Pertains to
Gulf War Illnesses, Vol 2: Pyridostigmine Bromide. Santa Monica, CA:
RAND; 1999:385.

6\. Cecchine G, Golomb BA, Hilborne LH, Spektor DM, Anthony CR. A Review
of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol
8: Pesticides. Santa Monica, CA: RAND; 2000:182.

7\. Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate
pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and
NMDA receptors. *Toxicol Appl Pharmacol*. 2001;177:17-25.

8\. Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic
receptor-mediated pyridostigmine-induced neuronal apoptosis.
*Neurotoxicology*. 2000;21:541-552.

9\. Pascuzzo GJ, Akaike A, Maleque MA, et al. The nature of the
interactions of pyridostigmine with the nicotinic acetylcholine
receptor-ionic channel complex I. Agonist, desensitizing, and binding
properties. *Mol Pharmacol*. 1984;25:92-101.

10\. Tandon P, Padilla S, Barone S, Pope CN, Tilson HA. Fenthion
produces a persistent decrease in muscarinic receptor function in the
adult rat retina. *Toxicol Appl Pharmacol*. 1994;125:271-280.

11\. Tandon P, Willig S, Pope CN, Padilla S, Tilson HA. Dose-response
study of the tissue-specific effects of fenthion on receptor function in
rat CNS. *Toxicologist*. 1994;14:257.

12\. Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison
of actions of carbamate anticholinesterses on the nicotinic
acetylcholine receptor. *Molecular Pharmacology*. 1985;27:343-348.

13\. Gupta RC, Patterson GT, Dettbarn W-D. Mechanisms of toxicity and
tolerance to diisopropylphosphorofluoridate at the neuromuscular
junction of the rat. *Toxicology and Applied Pharmacology*.
1986;84:541-550.

14\. Eskenazi B, Bradman A, Castorina R. Exposures of children to
organophosphate pesticides and their potential adverse health effects.
*Environ Health Perspect*. 1999;107 Suppl 3:409-19.

15\. Costa LG, Schwab BW, Murphy SD. Tolerance to anticholinesterase
compounds in mammals. *Toxicology*. 1982;25:79-97.

16\. Buccafusco JJ. Chronic organophosphorus exposure and cognition.
*1999 Annual Report to Congress on Gulf War Veterans\' Illnesses*.
2000:101.

17\. Lev-Lehman E, Evron T, Broide R, et al. Synaptogenesis and myopathy
under acetylcholinesterase overexpression. *Journal of Molecular
Neuroscience*. 2000;14:93-105.

18\. Robinson D, McGee R. Agonist-induced regulation of neuronal
nicotinic acetylcholine receptor of PC12 cells. *Molecular
Pharmacology*. 1985;27:409-417.

19\. Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison
of actions of carbamate anticholinesterses on the nicotinic
acetylcholine receptor. *Molecular Pharmacology*. 1985;27:343-348.

20\. Shaw K-P, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX.
The reversible cholinesterase inhibitor physostgmine has channelblocking
and agonist efects on the acetylcholine receptor-ion channel complex.
*Molecular Pharmacology*. 1985;28:527-238.

21\. Anderson RJ, Chamberlain WL, Roesner M, Dacko C, Robertson DG.
Decreased tetanic contracture of rat skeletal muscle induced by
pyridostigmine. *J Toxicol Environ Health*. 1986;18:221-230.

22\. Haley RW, Billecke S, La Du BN. Association of low PON1 type Q
(type A) arylesterase activity with neurologic symptom complexes in Gulf
War veterans. *Toxicol Appl Pharmacol*. 1999;157:227-33.

23\. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum
paraoxonase (PON1) isozymes: the quantitative analysis of isozymes
affecting individual sensitivity to environmental chemicals. *Drug Metab
Dispos*. 2001;29:566-9.

24\. Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian
Gulf War Veterans self-reporting Gulf War Syndrome. *Biochem Biophys Res
Commun*. 2000;276:729-33.

25\. Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1)
polymorphisms in farmers attributing ill health to sheep dip. *Lancet*.
2002;359:763-4.

26\. Cecchine G, Golomb B, Hilborne LH, Spektor DM, Anthony CR. A Review
of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol
8: Pesticides. Washington, DC: RAND; 2000:182.

27\. Cherry N, Creed F, Silman A, et al. Health and exposures of United
Kingdom Gulf war veterans. Part II: The relation of health to exposure.
*Occup Environ Med*. 2001;58:299-306.

28\. Gray GC, Reed RJ, Kaiser KS, Smith TC, Gastanaga VM. Self-reported
symptoms and medical conditions among 11,868 Gulf War-era veterans: the
Seabee Health Study. *Am J Epidemiol*. 2002;155:1033-44.

29\. Haley RW, Kurt TL. Self-reported exposure to neurotoxic chemical
combinations in the Gulf War. A cross-sectional epidemiologic study.
*Jama*. 1997;277:231-7.

30\. Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM. Illnesses among
United States veterans of the Gulf War: a population-based survey of
30,000 veterans. *J Occup Environ Med*. 2000;42:491-501.

31\. Kang H, Mahan CM, Lee KY, et al. Evidence for a deployment-related
Gulf War syndrome by factor analysis. : Arch Environ Health; 2002:58.

32\. Kroenke K, Koslowe P, Roy M. Symptoms in 18,495 Persian Gulf War
veterans. Latency of onset and lack of association with self-reported
exposures. *Journal of Occupational and Environmental Medicine*.
1998;40:520-8.

33\. Proctor SP, Harley R, Wolfe J, Heeren T, White RF. Health-related
quality of life in Persian Gulf War Veterans. *Mil Med*. 2001;166:510-9.

34\. Reid S, Hotopf M, Hull L, Ismail K, Unwin C, Wessely S. Multiple
chemical sensitivity and chronic fatigue syndrome in British Gulf War
veterans. *Am J Epidemiol*. 2001;153:604-9.

35\. Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and
the long-term subjective health status of a sample of female reserve
component Gulf War veterans: a brief report. *Psychol Rep*.
2001;88:306-8.

36\. Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and
the long-term subjective health status of a sample of over 700 male
Reserve Component Gulf War era veterans. *Psychol Rep*. 2002;90:707-21.

37\. White RF, Proctor SP, Heeren T, et al. Neuropsychological function
in Gulf War veterans: relationships to self-reported toxicant exposures.
*Am J Ind Med*. 2001;40:42-54.

38\. McCauley LA, Rischitelli G, Lambert WE, Lasarev M, Sticker DL,
Spencer PS. Symptoms of Gulf War veterans possibly exposed to
organophosphate chemical warfare agents at Khamisiyah, Iraq. *Int J
Occup Environ Health*. 2001;7:79-89.

39\. McCauley L, Lasarev M, Sticker D, Rischitelli D, Spencer P. Illness
experience of Gulf War veterans possibly exposed to chemical warfare
agents. *Am J Prev Med*. 2002;23:200.

40\. Gray G, Coate B, Anderson C, et al. The postwar hospitalization
experience of US veterans of the Persian Gulf War. *New Engl J Med*.
1996;335:1505-1513.

41\. Gray GC, Smith TC, Kang HK, Knoke JD. Are Gulf War veterans
suffering war-related illnesses? Federal and civilian hospitalizations
examined, June 1991 to December 1994. *Am J Epidemiol*. 2000;151:63-71.

42\. Kaiser KS. Pyridostigmine bromide intake during the Persian Gulf
War is not associated with postwar handgrip strength. *Mil Med*.
2000;165:165-8.

43\. Golomb BA. Chapter 14. Chronic Effect. In: A Review of the
Scientific Literature as it Pertains to Gulf War Illnesses, Vol 2:
Pyridostigmine Bromide. Santa Monica, CA: RAND; 1999:385.

44\. Lotti M. Low-level exposures to organophosphorus esters and
peripheral nerve function. *Muscle Nerve*. 2002;25:492-504.

45\. Ray DE. Chronic effects of low level exposure to
anticholinesterases. *Toxicology Letters*. 1998;95:26.

46\. Glass-Marmor L, Beitner R. Effects of carbamylcholine and
pyridostigmine on mitochondrial-bound hexokinase in skeletal muscle and
heart. *Biochem Mol Med*. 1996;57:67-70.

47\. Francesconi R, Hubbard R, Mager M. Effects of pyridostigmine on
ability of rats to work in the heat. *J Appl Physiol*. 1984;56:891-5.

48\. Babu SR, Buckenmeyer P, Knowlton RG, Somani SM. Effect of
physostigmine on plasma lactate and pyruvate in untrained/trained rats.
*Pharmacol Biochem Behav*. 1992;42:67-73.

49\. Buckenmeyer PJ, Babu SR, Knowlton RG, Somani SM. Effect of
concurrent exercise and physostigmine on lactate and pyruvate in plasma,
muscle, and brain tissue of rats. *Pharmacol Biochem Behav*.
1994;47:779-88.

50\. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs
and mitochondrial function: effects of HMG-CoA reductase inhibitors on
serum ubiquinone and blood lactate/pyruvate ratio. *British Journal of
Clinical Pharmacology*. 1996;42:333-7.

51\. Chariot P, Monnet I, Mouchet M, et al. Determination of the blood
lactate:pyruvate ratio as a noninvasive test for the diagnosis of
zidovudine myopathy. *Arthritis Rheum*. 1994;37:583-6.

52\. Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10
improves mitochondrial respiration in patients with mitochondrial
cytopathies. An in vivo study on brain and skeletal muscle by
phosphorous magnetic resonance spectroscopy. *Cellular and Molecular
Biology*. 1997;43:741-9.

53\. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial
encephalomyopathy associated with a muscle coenzyme Q10 deficiency.
*Journal of the Neurological Sciences*. 1998;156:41-6.

54\. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial
encephalomyopathies. Short-term double-blind, crossover study. *European
Neurology*. 1997;37:212-8.

55\. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial
encephalomyopathy with coenzyme Q10 deficiency. *Neurology*.
1997;48:1238-43.

56\. Fosslien E. Mitochondrial medicine\--molecular pathology of
defective oxidative phosphorylation. *Ann Clin Lab Sci*. 2001;31:25-67.

57\. Alleva R, Tomasetti M, Andera L, et al. Coenzyme Q blocks
biochemical but not receptor-mediated apoptosis by increasing
mitochondrial antioxidant protection. *FEBS Lett*. 2001;503:46-50.

58\. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10
reverses pathological phenotype and reduces apoptosis in familial CoQ10
deficiency. *Neurology*. 2001;57:515-8.

59\. Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q
protects cells against serum withdrawal-induced apoptosis by inhibition
of ceramide release and caspase-3 activation. *Antioxid Redox Signal*.
2000;2:263-75.

60\. Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some
circumstances block apoptosis, and this effect is mediated through
mitochondria. *Ann N Y Acad Sci*. 1999;887:31-47.

61\. Mosca L, Marcellini S, Perluigi M, et al. Modulation of apoptosis
and improved redox metabolism with the use of a new antioxidant formula.
*Biochem Pharmacol*. 2002;63:1305-14.

62\. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q
deficiency in familial mitochondrial encephalomyopathy. *Proc Natl Acad
Sci U S A*. 1989;86:2379-82.

63\. Tedeschi D, Lombardi V, Mancuso M, et al. Potential involvement of
ubiquinone in myotonic dystrophy pathophysiology: new diagnostic
approaches for new rationale therapeutics. *Neurol Sci*.
2000;21:S979-80.

64\. Takusa Y, Yamaguchi S. \[Myopathies with miscellaneous disorders
related to mitochondrial fatty acid oxidation: defective synthesis of
ketone body, long-chain fatty acid transport defect, and muscular
coenzyme Q10 deficiency\]. *Ryoikibetsu Shokogun Shirizu*. 2001:90-4.

65\. Folkers K, Simonsen R. Two successful double-blind trials with
coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic
atrophies. *Biochimica et Biophysica Acta*. 1995;1271:281-6.

66\. Shimomura Y, Suzuki M, Sugiyama S, Hanaki Y, Ozawa T. Protective
effect of coenzyme Q10 on exercise-induced muscular injury. *Biochem
Biophys Res Commun*. 1991;176:349-55.

67\. Elble R, Giacobini E, Higgins C. Choline levels are increased in
cerebrospinal fluid of Alzheimer patients. *Neurobiol Aging*.
1989;10:45-50.

68\. Berrettini WH, Garrick NA, Nurnberger JI, Jr., et al. Intravenous
physostigmine increases cerebrospinal fluid neuropeptide-Y. *Biol
Psychiatry*. 1989;26:623-30.

69\. Davis KL, Faull KF, Hollister LE, Barchas JD, Berger PA.
Alterations in cerebrospinal fluid dopamine metabolites following
physostigmine infusion. *Psychopharmacology (Berl)*. 1981;72:155-60.

70\. Kaye JA, May C, Atack JR, et al. Cerebrospinal fluid neurochemistry
in the myoclonic subtype of Alzheimer\'s disease. *Ann Neurol*.
1988;24:647-50.

71\. Jolkkonen J, Soininen H, Halonen T, et al. Somatostatin-like
immunoreactivity in the cerebrospinal fluid of patients with
Parkinson\'s disease and its relation to dementia. *J Neurol Neurosurg
Psychiatry*. 1986;49:1374-7.

72\. Gomez S, Davous P, Rondot P, Faivre-Bauman A, Valade D, Puymirat J.
Somatostatin-like immunoreactivity and acetylcholinesterase activities
in cerebrospinal fluid of patients with Alzheimer disease and senile
dementia of the Alzheimer type. *Psychoneuroendocrinology*.
1986;11:69-73.

73\. Hartikainen P, Reinikainen KJ, Soininen H, Sirvio J, Soikkeli R,
Riekkinen PJ. Neurochemical markers in the cerebrospinal fluid of
patients with Alzheimer\'s disease, Parkinson\'s disease and amyotrophic
lateral sclerosis and normal controls. *J Neural Transm Park Dis Dement
Sect*. 1992;4:53-68.

74\. Davis KL, Hollister LE, Goodwin FK, Gordon EK. Neurotransmitter
metabolites in the cerebrospinal fluid of man following physostigmine.
*Life Sci*. 1977;21:933-6.

75\. Popovic M, Popovic N, Jovanova-Nesic K, et al. Effect of
physostigmine and verapamil on active avoidance in an experimental model
of Alzheimer\'s disease. *Int J Neurosci*. 1997;90:87-97.

76\. Peskind ER, Wingerson D, Pascualy M, et al. Oral physostigmine in
Alzheimer\'s disease: effects on norepinephrine and vasopressin in
cerebrospinal fluid and plasma. *Biol Psychiatry*. 1995;38:532-8.

77\. degli Uberti EC, Bondanelli M, Margutti A, et al. Acute
administration of human galanin in normal subjects reduces the
potentiating effect of pyridostigmine-induced cholinergic enhancement on
release of norepinephrine and pancreatic polypeptide.
*Neuroendocrinology*. 1996;64:398-404.

78\. Araki S, Shibasaki H. \[Variations in serum amylase responding to
the neostigmine test in amyotrophic lateral sclerosis\]. *Igaku To
Seibutsugaku*. 1966;73:233-9.

79\. Gowen GF. A second look at the neostigmine morphine test. *Am
Surg*. 1989;55:640-4.

80\. Bell IR, Patarca R, Baldwin CM, Klimas NG, Schwartz GE, Hardin EE.
Serum neopterin and somatization in women with chemical intolerance,
depressives, and normals. *Neuropsychobiology*. 1998;38:13-8.

81\. Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L.
Cerebrospinal fluid acetylcholinesterase activity after long-term
treatment with donepezil and rivastigmina. *Mech Ageing Dev*.
2001;122:2057-62.

82\. Appleyard ME, Smith AD, Berman P, et al. Cholinesterase activities
in cerebrospinal fluid of patients with senile dementia of Alzheimer
type. *Brain*. 1987;110 ( Pt 5):1309-22.

83\. Appleyard ME, McDonald B. Acetylcholinesterase and
butyrylcholinesterase activities in cerebrospinal fluid from different
levels of the neuraxis of patients with dementia of the Alzheimer type.
*J Neurol Neurosurg Psychiatry*. 1992;55:1074-8.

84\. Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of
neostigmine for the treatment of acute colonic pseudo-obstruction. *Am
Surg*. 2001;67:265-8; discussion 268-9.

85\. Adams SB, MacHarg MA. Neostigmine methylsulfate delays gastric
emptying of particulate markers in horses. *Am J Vet Res*.
1985;46:2498-9.

86\. Amaro R, Rogers AI. Neostigmine infusion: new standard of care for
acute colonic pseudo-obstruction? *Am J Gastroenterol*. 2000;95:304-5.

87\. Alitalo I, Hietala A. Effects of atropine, isoprenaline,
neostigmine and practocol on cardiac arrhythmias induced by potassium in
anesthetized dogs. *Nord Vet Med*. 1977;29:498-501.

88\. Anzueto A, deLemos RA, Seidenfeld J, et al. Acute inhalation
toxicity of soman and sarin in baboons. *Fundam Appl Toxicol*.
1990;14:676-87.

89\. Haley RW, Vongpatanasin W, Wolfe GI, et al. Abnormal control of
heart rate variability in veterans with Gulf War Syndrome. Submitted for
publication.

90\. Ally A, Wilson LB, Nobrega AC, Mitchell JH. Cardiovascular effects
elicited by central administration of physostigmine via M2 muscarinic
receptors in conscious cats. *Brain Res*. 1995;677:268-76.

91\. Ally A, Hand GA, Mitchell JH. Central injection of physostigmine
attenuates exercise-induced pressor response in conscious cats. *Am J
Physiol*. 1997;273:R393-9.

92\. Jancin B. Pyridostigmine reduced orthostatic intolerance. *Internal
Medicine News*. 2002;June 15:32.

93\. Park KH, Long JP, Cannon JG. Reversal of antihypertensive
agent-induced postural hypotension with physostigmine. *Arch Int
Pharmacodyn Ther*. 1991;311:155-65.

94\. Hata S, Kunida H, Oyama Y. \[Antihypertensive effects of coenzyme
Q10 in essential hypertension\--in relation to the renin-aldosterone
system\]. *Horumon To Rinsho*. 1977;25:1019-23.

95\. Aoyagi M, Meyer JS, Deshmukh VD, et al. Central cholinergic control
of cerebral blood flow in the baboon. Effect of cholinesterase
inhibition with neostigmine on autoregulation and CO2 responsiveness. *J
Neurosurg*. 1975;43:689-705.

96\. Eneroth-Grimfors E, Lindblad LE, Westgren M, Ihrman-Sandahl C,
Bevegard S. Noninvasive test of microvascular endothelial function in
normal and hypertensive pregnancies. *Br J Obstet Gynaecol*.
1993;100:469-71.

97\. Arora S, Veves A, Caballaro AE, Smakowski P, LoGerfo FW. Estrogen
improves endothelial function. *J Vasc Surg*. 1998;27:1141-6; discussion
1147.

98\. Kubli S, Waeber B, Dalle-Ave A, Feihl F. Reproducibility of laser
Doppler imaging of skin blood flow as a tool to assess endothelial
function. *J Cardiovasc Pharmacol*. 2000;36:640-8.

99\. Williams MR, Westerman RA, Kingwell BA, et al. Variations in
endothelial function and arterial compliance during the menstrual cycle.
*J Clin Endocrinol Metab*. 2001;86:5389-95.

100\. Newton DJ, Khan F, Belch JJ. Assessment of microvascular
endothelial function in human skin. *Clin Sci (Lond)*. 2001;101:567-72.

101\. Elherik K, Khan F, McLaren M, Kennedy G, Belch JJ. Circadian
variation in vascular tone and endothelial cell function in normal
males. *Clin Sci (Lond)*. 2002;102:547-52.

102\. Lim SC, Caballero AE, Arora S, et al. The effect of hormonal
replacement therapy on the vascular reactivity and endothelial function
of healthy individuals and individuals with type 2 diabetes. *J Clin
Endocrinol Metab*. 1999;84:4159-64.

103\. Wirtschafter JD, Volk CR, Sawchuk RJ. Transaqueous diffusion of
acetylcholine to denervated iris sphincter muscle: a mechanism for the
tonic pupil syndrome (Adie syndrome). *Ann Neurol*. 1978;4:1-5.

104\. Fountoulakis K, Fotiou F, Iacovides A, et al. Changes in pupil
reaction to light in melancholic patients. *Int J Psychophysiol*.
1999;31:121-8.

105\. Elliott A, Carter C. Pupil size after extracapsular cataract
extraction and posterior chamber lens implantation: a prospective
randomized trial of epinephrine and acetylcholine. *Ophthalmic Surg*.
1989;20:591-4.

106\. Suzuki R, Kobayashi S, Yoshino H. \[The inhibitory cholinergic
innervation of the dilator on the movement of the pupil\]. *Nippon Ganka
Gakkai Zasshi*. 1984;88:1555-7.

107\. Naito M. \[The autonomic nervous system and eyes: the role of the
sympathetic nerve on extra-ocular muscle and pupil\]. *Nippon Ganka
Gakkai Zasshi*. 1971;75:988-95.

108\. Pohjanpelto P. \[Carbachol in cataract surgery used for
constriction of the pupil\]. *Duodecim*. 1969;85:1504-7.

109\. Cook JE, Kolka MA, Wenger CB. Chronic pyridostigmine bromide
administration: side effects among soldiers working in a desert
environment. *Mil Med*. 1992;157:250-4.

110\. Borland RG, Brennan DH, Nicholson AN, Smith PA. Studies on the
possible central and peripheral effects in man of a cholinesterase
inhibitor (pyridostigmine). *Hum Toxicol*. 1985;4:293-300.

111\. Goel A, Joseph S, Dutta TK. Organophosphate poisoning: predicting
the need for ventilatory support. *J Assoc Physicians India*.
1998;46:786-90.

112\. Kay CD, Morrison JD. The effects of ingestion of 60 mg
pyridostigmine bromide on contrast sensitivity in man. *Hum Toxicol*.
1988;7:347-52.

113\. Loupe DN, Newman NJ, Green RC, et al. Pupillary response to
tropicamide in patients with Alzheimer disease. *Ophthalmology*.
1996;103:495-503.

114\. Macic I, Maksimovic M, Erdeljan D, Stojadinovic L. \[Antagonism of
miosis induced by sarin and VX in rabbits\]. *Vojnosanit Pregl*.
1986;43:103-8.

115\. Nozaki H, Hori S, Shinozawa Y, et al. Secondary exposure of
medical staff to sarin vapor in the emergency room. *Intensive Care
Med*. 1995;21:1032-5.

116\. Nozaki H, Hori S, Shinozawa Y, et al. Relationship between pupil
size and acetylcholinesterase activity in patients exposed to sarin
vapor. *Intensive Care Med*. 1997;23:1005-7.

117\. Rengstorff RH. Accidental exposure to sarin: vision effects. *Arch
Toxicol*. 1985;56:201-3.

118\. Sidell FR, Groff WA. The reactivatibility of cholinesterase
inhibited by VX and sarin in man. *Toxicol Appl Pharmacol*.
1974;27:241-52.

119\. Wiley RW, Kotulak JC, Behar I. The effects of pyridostigmine
bromide on visual performance. *Aviat Space Environ Med*.
1992;63:1054-9.

120\. Schneider R. A test for the assessment of the duration of the
action of neostigmine and of the relative potencies of various
anticholinesterases using the pupil of the mouse. *J Pharm Pharmacol*.
1970;22:298-301.

121\. Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning
with physostigmine. *Am J Emerg Med*. 1998;16:505-7.

122\. Crowell EB, Jr., Ketchum JS. The treatment of scopolamine-induced
delirium with physostigmine. *Clin Pharmacol Ther*. 1967;8:409-14.

123\. Wilhelm B, Wilhelm H, Streicher P, Ludtke H, Adler M.
\[Pupillography as an objective attention test\]. *Wien Med Wochenschr*.
1996;146:387-9.

124\. Wilhelm B, Wilhelm H, Ludtke H, Adler M, Streicher P.
\[Pupillography for objective vigilance assessment. Methodological
problems and possible solutions\]. *Ophthalmologe*. 1996;93:446-50.

125\. Morad Y, Lemberg H, Yofe N, Dagan Y. Pupillography as an objective
indicator of fatigue. *Curr Eye Res*. 2000;21:535-42.

126\. Danker-Hopfe H, Kraemer S, Dorn H, Schmidt A, Ehlert I, Herrmann
WM. Time-of-day variations in different measures of sleepiness (MSLT,
pupillography, and SSS) and their interrelations. *Psychophysiology*.
2001;38:828-35.

127\. Coelho F, Birks J. Physostigmine for Alzheimer\'s disease.
*Cochrane Database Syst Rev*. 2001:CD001499.

128\. Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week
randomized trial of controlled-release physostigmine in patients with
Alzheimer\'s disease. *Neurology*. 1999;52:1146-52.

129\. van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release
physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week
study with dose enrichment. Physostigmine Study Group. *Arch Gen
Psychiatry*. 2000;57:157-64.

130\. Memory enhancement with oral physostigmine in Alzheimer\'s
disease. *N Engl J Med*. 1983;308:720-1.

131\. Aigner TG, Mishkin M. The effects of physostigmine and scopolamine
on recognition memory in monkeys. *Behav Neural Biol*. 1986;45:81-7.

132\. Aigner TG, Mitchell SJ, Aggleton JP, et al. Effects of scopolamine
and physostigmine on recognition memory in monkeys with ibotenic-acid
lesions of the nucleus basalis of Meynert. *Psychopharmacology (Berl)*.
1987;92:292-300.

133\. Alagiakrishnan K, Wong W, Blanchette PL. Use of donepezil in
elderly patients with Alzheimer\'s disease\--a Hawaii based study.
*Hawaii Med J*. 2000;59:57-9.

134\. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L,
Nordberg A. Responder characteristics to a single oral dose of
cholinesterase inhibitor: a double-blind placebo-controlled study with
tacrine in Alzheimer patients. *Dement Geriatr Cogn Disord*.
2001;12:22-32.

135\. Arsland D, Laake K. \[Should Alzheimer disease be treated with
tacrine? Review of the literature\]. *Tidsskr Nor Laegeforen*.
1996;116:2791-4.

136\. Arendt T, Schugens MM, Bigl V. The cholinergic system and memory:
amelioration of ethanol-induced memory deficiency by physostigmine in
rat. *Acta Neurobiol Exp (Warsz)*. 1990;50:251-61.

137\. Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF.
Physostigmine and its effect on six patients with dementia. *Am J
Psychiatry*. 1981;138:829-30.

138\. Asthana S, Greig NH, Hegedus L, et al. Clinical pharmacokinetics
of physostigmine in patients with Alzheimer\'s disease. *Clin Pharmacol
Ther*. 1995;58:299-309.

139\. Lacey SC, Robinson KM, Umile E, et al. Evaluation of working
memory in Persian Gulf War veterans with chronic fatigue \[abstract\].
*Proceedings of the Conference on Federally Sponsored Gulf War Veteransí
Illnesses Research, Pentagon City, Jun 1999, 133.134*. 1999.

140\. Leclercq M, Couillet J, Azouvi P, et al. Dual task performance
after severe diffuse traumatic brain injury or vascular prefrontal
damage. *J Clin Exp Neuropsychol*. 2000;22:339-50.

141\. Overstreet DH, Miller CS, Janowsky DS, Russell RW. Potential
animal model of multiple chemical sensitivity with cholinergic
supersensitivity. *Toxicology*. 1996;111:119-34.

142\. Servatius RJ, Ottenweller JE, Beldowicz D, Guo W, Zhu G, Natelson
BH. Persistently exaggerated startle responses in rats treated with
pyridostigmine bromide. *J Pharmacol Exp Ther*. 1998;287:1020-8.

143\. Janowsky DS, el-Yousef K, Davis JM, Sekerke HJ. Parasympathetic
suppression of manic symptoms by physostigmine. *Arch Gen Psychiatry*.
1973;28:542-7.

144\. Janowsky D, Risch C, Parker D, Huey L, Judd L. Increased
vulnerability to cholinergic stimulation in affective disorder patients.
*Psychopharmacol Bull*. 1980;16:29-31.

145\. Janowsky DS, Risch SC, Judd LL, Huey LY, Parker D. Cholinergic
supersensitivity in affect disorder patients: Behavioral and
neuroendocrine observations. *Psychopharmacol Bull*. 1981;17:129-132.

146\. Janowsky D, Risch C, Gillin J. Adrenergic-cholinergic balance and
the treatment of affective disorders. *Prog Neuropsychopharmacol Biol
Psychiatry*. 1983;7:297-307.

147\. Janowsky D, Risch C. Cholinomimetic and anti cholinergic drugs
used to investigate an acetylcholine hypothesis of affective disorders
adn stress. *Drug Dev Res*. 1984.

148\. Bannon AW, Gunther KL, Decker MW. Is epibatidine really analgesic?
Dissociation of the activity, temperature, and analgesic effects of
(+/-)-epibatidine. *Pharmacol Biochem Behav*. 1995;51:693-698.

149\. Avlonitou E, Elizondo R. Effects of atropine and pyridostigmine in
heat-stressed patas monkeys. *Aviat Space Environ Med*. 1988;59:544-8.

150\. Barar FS, Madan BR. Tremorine-oxotremorine-induced tremor,
hypothermia and analgesia, and physostigmine toxicity, in mice after
pretreatment with beta-adrenoceptor antagonists. *J Pharm Pharmacol*.
1976;28:286-9.

151\. Clement JG. Variability of sarin-induced hypothermia in mice:
investigation into incidence and mechanism. *Biochem Pharmacol*.
1991;42:1316-8.

152\. Francesconi R, Hubbard R, Matthew C, Leva N, Young J, Pease V.
Oral pyridostigmine administration in rats: effects on thermoregulation,
clinical chemistry, and performance in the heat. *Pharmacol Biochem
Behav*. 1986;25:1071-5.

153\. Gordon CJ. 24-hour control of body temperature in the rat: II.
Diisopropyl fluorophosphate-induced hypothermia and hyperthermia.
*Pharmacol Biochem Behav*. 1994;49:747-754.

154\. Epstein Y, Seidman DS, Moran D, Arnon R, Arad M, Varssano D.
Heat-exercise performance of pyridostigmine-treated subjects wearing
chemical protective clothing. *Aviat Space Environ Med*. 1990;61:310-3.

155\. Epstein Y, Arnon R, Moran D, Seidman DS, Danon Y. Effect of
pyridostigmine on the exercise-heat response of man. *Eur J Appl Physiol
Occup Physiol*. 1990;61:128-32.

156\. Kassa J, Koupilova M, Herink J, Vachek J. The long-term influence
of low-level sarin exposure on behavioral and neurophysiological
functions in rats. *Acta Medica (Hradec Kralove)*. 2001;44:21-7.

157\. Kolka MA, Stephenson LA. Human temperature regulation during
exercise after oral pyridostigmine administration. *Aviat Space Environ
Med*. 1990;61:220-4.

158\. Lin MT, Wang HC, Chandra A. The effects on thermoregulation of
intracerebroventricular injections of acetylcholine, pilocarpine,
physostigmine, atropine and hemicholinium in the rat.
*Neuropharmacology*. 1980;19:561-5.

159\. Matthew CB, Hubbard RW, Francesconi RP. Atropine, diazepam, and
physostigmine: thermoregulatory effects in the heat-stressed rat. *Life
Sci*. 1989;44:1921-7.

160\. Matthew CB, Francesconi RP, Hubbard RW. Physostigmine:
dose-response effects on endurance and thermoregulation during exercise.
*Life Sci*. 1992;50:39-44.

161\. Maickel RP, Kinney DR, Ryker DL, Nichols MB. Antagonism of
physostigmine induced hypothermia and neuroendocrine changes following
exposure to different environmental temperatures. *Prog
Neuropsychopharmacol Biol Psychiatry*. 1991;15:873-84.

162\. Monda M, Viggiano A, De Luca V. Administration of muscimol into
the posterior hypothalamus reduces hyperthermia induced by hippocampal
neostigmine injection. *Brain Res*. 2000;887:344-9.

163\. Prusaczyk WK, Sawka MN. Effects of pyridostigmine bromide on human
thermoregulation during cold water immersion. *J Appl Physiol*.
1991;71:432-7.

164\. Roberts DE, Sawka MN, Young AJ, Freund BJ. Pyridostigmine bromide
does not alter thermoregulation during exercise in cold air. *Can J
Physiol Pharmacol*. 1994;72:788-93.

165\. Sharkawi M. Morphine hyperthermia in the rat: its attenuation by
physostigmine. *Br J Pharmacol*. 1972;44:544-8.

166\. Stephenson LA, Kolka MA. Acetylcholinesterase inhibitor,
pyridostigmine bromide, reduces skin blood flow in humans. *Am J
Physiol*. 1990;258:R951-7.

167\. Wenger CB, Latzka WA. Effects of pyridostigmine bromide on
physiological responses to heat, exercise, and hypohydration. *Aviat
Space Environ Med*. 1992;63:37-45.

168\. Wenger B, Quigley MD, Kolka MA. Seven-day pyridostigmine
administration and thermoregulation during rest and exercise in dry
heat. *Aviat Space Environ Med*. 1993;64:905-11.

169\. Billet S, Cant NB, Hall WC. Cholinergic projections to the visual
thalamus and superior colliculus. *Brain Res*. 1999;847:121-3.

170\. Lee PH, Schmidt M, Hall WC. Excitatory and inhibitory circuitry in
the superficial gray layer of the superior colliculus. *J Neurosci*.
2001;21:8145-53.

171\. Aizawa H, Kobayashi Y, Yamamoto M, Isa T. Injection of nicotine
into the superior colliculus facilitates occurrence of express saccades
in monkeys. *J Neurophysiol*. 1999;82:1642-6.

172\. Binns KE. The synaptic pharmacology underlying sensory processing
in the superior colliculus. *Prog Neurobiol*. 1999;59:129-59.

173\. Wichmann T, Illing RB, Starke K. Evidence for a neurotransmitter
function of acetylcholine in rabbit superior colliculus. *Neuroscience*.
1987;23:991-1000.

174\. Beninato M, Spencer RF. A cholinergic projection to the rat
superior colliculus demonstrated by retrograde transport of horseradish
peroxidase and choline acetyltransferase immunohistochemistry. *J Comp
Neurol*. 1986;253:525-38.

175\. Weldon DA, Calabrese LC, Nicklaus KJ. Rotational behavior
following cholinergic stimulation of the superior colliculus in rats.
*Pharmacol Biochem Behav*. 1983;19:813-20.

176\. Pazdernik TL, Cross RS, Mewes K, Samson F, Nelson SR. Superior
colliculus activation by retinal nicotinic ganglion cells: a
2-deoxyglucose study. *Brain Res*. 1982;243:197-200.

177\. Kasser RJ, Cheney PD. DFP action on rat superior colliculus:
localization and role of cholinergic receptors. *Neurotoxicology*.
1987;8:607-22.

178\. Kang HK, Bullman TA. Mortality among US veterans of the Persian
Gulf War: 7-year follow-up. *Am J Epidemiol*. 2001;154:399-405.

179\. Kang HK, Bullman TA. Mortality among U.S. veterans of the Persian
Gulf War \[see comments\]. *N Engl J Med*. 1996;335:1498-504.

180\. Bell NS, Amoroso PJ, Wegman DH, Senier L. Proposed explanations
for excess injury among veterans of the Persian Gulf War and a call for
greater attention from policymakers and researchers. *Inj Prev*.
2001;7:4-9.

181\. Haley RW, Marshall WW, McDonald GG, Daugherty MA, Petty F,
Fleckenstein JL. Brain abnormalities in Gulf War syndrome: Evaluation
with 1H MR spectroscopy. *Radiology*. 2000;215:807-817.

182\. Mayberg HS. Clinical correlates of PET- and SPECT-identified
defects in dementia. *Journal of Clinical Psychiatry*. 1994;55:12-21.

183\. Eustache F, Desgranges B, Giffard B, de la Sayette V, Baron J-C.
Entorhinal cortex disruption causes memory deficit in early Alzheimer\'s
disease as shown by PET. *Neuroreport*. 2001;12:683-685.

184\. Tani Y, Ishihara T, Kanai T, et al.
6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP, SUN 0588) acts on the
brain muscarinic and nicotinic cholinergic receptors as evaluated by
positron emission tomography (PET) in rhesus monkey. *Adv Exp Med Biol*.
1993;338:331-4.

185\. Nordberg A, Amberla K, Shigeta M, et al. Long-term tacrine
treatment in three mild Alzheimer patients: effects on nicotinic
receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive
abilities. *Alzheimer Dis Assoc Disord*. 1998;12:228-37.

186\. Ding YS, Gatley SJ, Fowler JS, et al. Mapping nicotinic
acetylcholine receptors with PET. *Synapse*. 1996;24:403-7.

187\. Chefer SI, Horti AG, Koren AO, et al. 2-\[18F\]F-A-85380: a PET
radioligand for alpha4beta2 nicotinic acetylcholine receptors.
*Neuroreport*. 1999;10:2715-21.

188\. Dolci L, Dolle F, Valette H, et al. Synthesis of a fluorine-18
labeled derivative of epibatidine for in vivo nicotinic acetylcholine
receptor PET imaging. *Bioorg Med Chem*. 1999;7:467-79.

189\. Horti A, Scheffel U, Stathis M, et al. Fluorine-18-FPH for PET
imaging of nicotinic acetylcholine receptors. *J Nucl Med*.
1997;38:1260-5.

190\. Ding Y, Liu N, Wang T, et al. Synthesis and evaluation of
6-\[(18)F\]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for
nicotinic acetylcholine receptors. *Nucl Med Biol*. 2000;27:381-9.

191\. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T.
Brain muscarinic receptors in progressive supranuclear palsy and
Parkinson\'s disease: a positron emission tomographic study. *J Neurol
Neurosurg Psychiatry*. 1998;65:155-63.

192\. Mentis MJ, Sunderland T, Lai J, et al. Muscarinic versus nicotinic
modulation of a visual task. a pet study using drug probes.
*Neuropsychopharmacology*. 2001;25:555-64.

193\. Furey ML, Pietrini P, Haxby JV, et al. Cholinergic stimulation
alters performance and task-specific regional cerebral blood flow during
working memory. *Proc Natl Acad Sci U S A*. 1997;94:6512-6.

194\. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of
cerebral acetylcholinesterase activity in aging and Alzheimer\'s
disease. *Neurology*. 1999;52:691-9.

195\. Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of
cortical acetylcholinesterase activity in association with cognitive
decline in Alzheimer\'s disease: a positron emission tomography study.
*Ann Neurol*. 2000;48:194-200.

196\. Meltzer CC, Smith G, Dekosky ST, et al. Serotonin in aging,
late-life depression, and Alzheimer\'s disease: The emerging role of
functional imaging. *Neuropsychopharmacology*. 1998;18:407-430.

197\. Price JC, Kelley DE, Ryan CM, et al. PET imaging of serotonin-1A
receptors in type 2 diabetes: Evidence of increased binding. *Journal of
Nuclear Medicine*. 2001;42:18P.

198\. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L.
Cognitive deficits in Huntington\'s disease are predicted by
dopaminergic PET markers and brain volumes. *Brain*. 1997;120:2207-2217.

199\. Schroeder U, Kuehler A, Haslinger B, et al. Subthalamic nucleus
stimulation affects striato-anterior cingulate cortex circuit in a
response conflict task: A PET study. *Brain*. 2002;125:1995-2004.

200\. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive
decline in normal elderly subjects with
2-(18F)fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).
*Proceedings of the National Academy of Sciences of the United States of
America*. 2001;98:10966-10971.

201\. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic
modulation of high-level cognition in Parkinson\'s disease: The role of
the prefrontal cortex revealed by PET. *Brain*. 2002;125:584-594.

202\. Arakawa K, Peachey NS, Celesia G, Rubboli G. Component-specific
effects of physostigmine on the cat visual evoked potential. *Exp Brain
Res*. 1993;95:271-6.

203\. Thierry G, Doyon B, Demonet J-F. ERP mapping in phonological and
lexical semantic monitoring tasks: A study complementing previous PET
results. *NeuroImage*. 1998;8:391-408.

204\. Abdullaev YG, Posner MI. Event-related brain potential imaging of
semantic encoding during processing single words. *NeuroImage*.
1998;7:1-13.

205\. Gazzard MF, Thomas DP. A comparative study of central visual field
changes induced by sarin vapour and physostigmine eye drops. *Exp Eye
Res*. 1975;20:15-21.

206\. Alderdice MT. Physostigmine, but not neostigmine, inhibits
acetylcholine release. *Brain Res*. 1979;178:596-9.

207\. Alderdice MT. Further comparison of the effects of physostigmine
and neostigmine on frog neuromuscular transmission. *Clin Exp Pharmacol
Physiol*. 1982;9:35-43.

208\. Abdel-Rahman A, Shetty A, Abou-Donia M. Disruption of the
blood-brain barrier and neuronal cell death in cingulate cortex, dentate
gyrus, thalamus, and hypothalamus in a rat model of gulf-war syndrome.
*Neurobiol Dis*. 2002;10:306.

209\. Abdel-Rahman A, Shetty AK, Abou-Donia MB. Acute exposure to sarin
increases blood brain barrier permeability and induces neuropathological
changes in the rat brain: dose-response relationships. *Neuroscience*.
2002;113:721-41.

210\. Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic
receptor-mediated pyridostigmine-induced neuronal apoptosis.
*Neurotoxicology*. 2000;21:541-52.

211\. Alberts P, Ogren VR. Sarin and soman depress \[3H\]acetylcholine
secretion in guinea-pig ileum myenteric plexus. *Acta Physiol Scand*.
1985;125:347-8.

212\. Arroyo G, Aldea M, Fuentealba J, Garc a AG. \[Nicotinic Receptor,
galantamine and Alzheimer disease\]. *Rev Neurol*. 2002;34:1057-65.

213\. Akaike A, Ikeda SR, Brookes N, Pascuzzo GJ, Rickett DL,
Albuquerque EX. The nature of the interactions of pyridostigmine with
the nicotinic acetylcholine receptor-ionic channel complex. II. Patch
clamp studies. *Mol Pharmacol*. 1984;25:102-12.

214\. Arendt T, Bruckner MK, Lange M, Bigl V. Changes in
acetylcholinesterase and butyrylcholinesterase in Alzheimer\'s disease
resemble embryonic development\--a study of molecular forms. *Neurochem
Int*. 1992;21:381-96.

215\. Antonelli T, Beani L, Bianchi C, Pedata F, Pepeu G. Changes in
synaptosomal high affinity choline uptake following electrical
stimulation of guinea-pig cortical slices: effect of atropine and
physostigmine. *Br J Pharmacol*. 1981;74:525-31.

216\. Abdel-Rahman A, Shetty AK, Abou-Donia MB. Subchronic dermal
application of N,N-diethyl m-toluamide (DEET) and permethrin to adult
rats, alone or in combination, causes diffuse neuronal cell death and
cytoskeletal abnormalities in the cerebral cortex and the hippocampus,
and Purkinje neuron loss in the cerebellum. *Exp Neurol*.
2001;172:153-71.

217\. Aizenman E, Bierkamper GG, Stanley EF. Botulinum toxin prevents
stimulus-induced backfiring produced by neostigmine in the mouse phrenic
nerve-diaphragm. *J Physiol*. 1986;372:395-404.

218\. Amaki Y, Kobayashi K, Kaneko M. \[The effect of neostigmine and
edrophonium on the MEPP frequency\]. *Masui*. 1989;38:760-6.

219\. Anderson RJ, Chamberlain WL, Roesner M, Dacko C, Robertson DG.
Decreased tetanic contracture of rat skeletal muscle induced by
pyridostigmine. *J Toxicol Environ Health*. 1986;18:221-30.

220\. Anderson RJ. Effect of pyridostigmine on tetanic contracture of
innervated and denervated rat skeletal muscle. *Neurotoxicology*.
1987;8:553-60.

221\. Anderson RJ, Chamberlain WL. Pyridostigmine-induced decrement in
skeletal muscle contracture is not augmented by soman.
*Neurotoxicology*. 1988;9:89-96.

222\. Damodaran TV, Bilska MA, Rahman AA, Abou-Doni MB. Sarin causes
early differential alteration and persistent overexpression in mRNAs
coding for glial fibrillary acidic protein (GFAP) and vimentin genes in
the central nervous system of rats. *Neurochem Res*. 2002;27:407-15.

223\. Glass-Marmor L, Chen-Zion M, Beitner R. Effects of carbamylcholine
and pyridostigmine on cytoskeleton-bound and cytosolic
phosphofructokinase and ATP levels in different rat tissues. *Gen
Pharmacol*. 1996;27:1241-6.

224\. Somani SM, Kutty RK, Krishna G. Eseroline, a metabolite of
physostigmine, induces neuronal cell death. *Toxicol Appl Pharmacol*.
1990;106:28-37.

225\. Spencer PS, McCauley LA, Lapidus JA, Lasarev M, Joos SK, Storzbach
D. Self-reported exposures and their association with unexplained
illness in a population-based case-control study of Gulf War veterans.
*J Occup Environ Med*. 2001;43:1041-56.

226\. Abu-Qare AW, Abou-Donia MB. Combined exposure to sarin and
pyridostigmine bromide increased levels of rat urinary 3-nitrotyrosine
and 8-hydroxy-2\'-deoxyguanosine, biomarkers of oxidative stress.
*Toxicol Lett*. 2001;123:51-8.

227\. Abu-Qare AW, Suliman HB, Abou-Donia MB. Induction of urinary
excretion of 3-nitrotyrosine, a marker of oxidative stress, following
administration of pyridostigmine bromide, DEET (N,N-diethyl-m-toluamide)
and permethrin, alone and in combination in rats. *Toxicol Lett*.
2001;121:127-34.

228\. Artru AA, Michenfelder JD. A re-examination of
physostigmine-induced cerebral protection in the hypoxic mouse. A
critical assessment of the model. *Stroke*. 1980;11:197-9.

229\. Andjelkovic DS, Terzic MR. The effects of physostigmine on the
oxygen uptake in rat brain tissue. *Experientia*. 1979;35:372-3.

230\. Rupreht J, Schneck HJ, Dworacek B. \[Physostigmine\--recent
pharmacologic data and their significance for practical use\].
*Anaesthesiol Reanim*. 1989;14:235-41.

231\. Bradley RJ, Sterz R, Peper K. Agonist and inhibitory effects of
pyridostigmine at the neuromuscular junction. *Brain Res*.
1986;376:199-203.

232\. Zheng JQ, He XP, Yang AZ, Liu CG. Neostigmine competitively
inhibited nicotinic acetylcholine receptors in sympathetic neurons.
*Life Sci*. 1998;62:1171-8.

233\. Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX.
The reversible cholinesterase inhibitor physostigmine has
channel-blocking and agonist effects on the acetylcholine receptor-ion
channel complex. *Mol Pharmacol*. 1985;28:527-38.

234\. Zheng JQ, He XP, Yang AZ, Liu CG. Physostigmine blocked nicotinic
acetylcholine receptors in rat sympathetic ganglion neurons. *Zhongguo
Yao Li Xue Bao*. 1997;18:508-11.

235\. Navratil J, Sklenovsky A, Camela Z, Rypka M. The labilizing and
stabilizing effect of physostigmine on CNS. *Acta Univ Palacki Olomuc
Fac Med*. 1990;126:39-44.

236\. Navratil J, Sklenovsky A, Chmela Z, Rypka M. Increase of
nonesterified fatty acids in CNS after physostigmine application.
*Homeost Health Dis*. 1991;33:172-3.

237\. Tapia R. Release and uptake of glutamate as related to
excitotoxicity. *Rev Bras Biol*. 1996;56 Su 1 Pt 1:165-74.

238\. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of
multiple sclerosis. *Nat Med*. 2000;6:67-70.

239\. Chen Q, Veenman CL, Reiner A. Cellular expression of ionotropic
glutamate receptor subunits on specific striatal neuron types and its
implication for striatal vulnerability in glutamate receptor-mediated
excitotoxicity. *Neuroscience*. 1996;73:715-31.

240\. Paschen W. Glutamate excitotoxicity in transient global cerebral
ischemia. *Acta Neurobiol Exp (Warsz)*. 1996;56:313-22.

241\. Zhang J, Price JO, Graham DG, Montine TJ. Secondary excitotoxicity
contributes to dopamine-induced apoptosis of dopaminergic neuronal
cultures. *Biochem Biophys Res Commun*. 1998;248:812-6.

242\. Hugon J, Vallat JM, Dumas M. \[Role of glutamate and
excitotoxicity in neurologic diseases\]. *Rev Neurol (Paris)*.
1996;152:239-48.

243\. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic
lateral sclerosis. *J Neurol*. 1997;244 Suppl 2:S3-14.

244\. US links motor neurone disease with Gulf War service. *BMJ*.
2002;324:65.

245\. Nguimfack Mbodie PC. \[Do the glutamate excitotoxicity theory and
potential free radicals implication in schizophrenia aetiopathogenesis
provide a new enlightenment to links between: genome, environment and
biology in the determinism of that disorder?\]. *Encephale*.
2002;28:147-53.

246\. Doble A. The role of excitotoxicity in neurodegenerative disease:
implications for therapy. *Pharmacol Ther*. 1999;81:163-221.

247\. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated
excitotoxicity in Parkinson\'s disease: a target for neuroprotection.
*Ann Neurol*. 1998;44:S175-88.

248\. Beal MF. Excitotoxicity and nitric oxide in Parkinson\'s disease
pathogenesis. *Ann Neurol*. 1998;44:S110-4.

249\. Zhang J, Price JO, Graham DG, Montine TJ. Secondary excitotoxicity
contributes to dopamine-induced apoptosis of dopaminergic neuronal
cultures. *Biochem Biophys Res Commun*. 1998;248:812-6.

250\. Hugon J, Vallat JM, Dumas M. \[Role of glutamate and
excitotoxicity in neurologic diseases\]. *Rev Neurol (Paris)*.
1996;152:239-48.

251\. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang GJ, Labruyere J.
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson\'s
and Huntington\'s diseases. *Exp Neurol*. 1990;108:269-72.

252\. Greene JG, Greenamyre JT. Bioenergetics and glutamate
excitotoxicity. *Prog Neurobiol*. 1996;48:613-34.

253\. Tymianski M, Sattler R, Zabramski JM, Spetzler RF.
Characterization of neuroprotection from excitotoxicity by moderate and
profound hypothermia in cultured cortical neurons unmasks a
temperature-insensitive component of glutamate neurotoxicity. *J Cereb
Blood Flow Metab*. 1998;18:848-67.

254\. Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute
glutamate excitotoxicity in cultured cerebellar granule cells. *J
Neurochem*. 1996;67:2282-91.

255\. Nicholls DG, Budd SL. Mitochondria and neuronal glutamate
excitotoxicity. *Biochim Biophys Acta*. 1998;1366:97-112.

256\. Castilho RF, Ward MW, Nicholls DG. Oxidative stress, mitochondrial
function, and acute glutamate excitotoxicity in cultured cerebellar
granule cells. *J Neurochem*. 1999;72:1394-401.

257\. Schubert D, Piasecki D. Oxidative glutamate toxicity can be a
component of the excitotoxicity cascade. *J Neurosci*. 2001;21:7455-62.

258\. Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R.
Glucocorticoids mediate the stress-induced extracellular accumulation of
glutamate. *Brain Res*. 1994;655:251-4.

259\. Tombaugh GC, Yang SH, Swanson RA, Sapolsky RM. Glucocorticoids
exacerbate hypoxic and hypoglycemic hippocampal injury in vitro:
biochemical correlates and a role for astrocytes. *J Neurochem*.
1992;59:137-46.

260\. Suchecki D, Tiba PA, Tufik S. Paradoxical sleep deprivation
facilitates subsequent corticosterone response to a mild stressor in
rats. *Neurosci Lett*. 2002;320:45-8.

261\. Hairston IS, Ruby NF, Brooke S, et al. Sleep deprivation elevates
plasma corticosterone levels in neonatal rats. *Neurosci Lett*.
2001;315:29-32.

262\. Maelicke A, Coban T, Schrattenholz A, et al. Physostigmine and
neuromuscular transmission. *Ann N Y Acad Sci*. 1993;681:140-54.

263\. Aiello-Malmberg P, Bartolini A, Bartolini R, Galli A. Effects of
morphine, physostigmine and raphe nuclei stimulation on
5-hydroxytryptamine release from the cerebral cortex of the cat. *Br J
Pharmacol*. 1979;65:547-55.

264\. Anden NE. Effects of oxotremorine and physostigmine on the
turnover of dopamine in the corpus striatum and the limbic system. *J
Pharm Pharmacol*. 1974;26:738-40.

265\. Choi JY, Morris JC, Hsu CY. Aging and cerebrovascular disease.
*Neurol Clin*. 1998;16:687-711.

266\. Banks W, Kastin A. Aluminum increases permeability of the blood
brain barrier to labeled DSIP and ß-endorphin: possible implications for
senile and dialysis dementia. *Lancet*. 1983:1227-1229.

267\. Sinton CM, Fitch TE, Petty F, Haley RW. Stressful manipulations
that elevate corticosterone reduce blood brain barrier permeability to
pyridostigmine in the rat. *Toxicology and Applied Pharmacology*.
2000;165:99-105.

268\. Telang FW, Ding YS, Volkow ND, Molina PE, Gatley SJ.
Pyridostigmine, a carbamate acetylcholinesterase AChE inhibitor and
reactivator, is used prophylactically against chemical warfare agents.
*Nucl Med Biol*. 1999;26:249-50.

269\. Jones KH, Dechkovskaia AM, Herrick EA, Abdel-Rahman AA, Khan WA,
Abou-Donia MB. Subchronic effects following a single sarin exposure on
blood-brain and blood-testes barrier permeability, acetylcholinesterase,
and acetylcholine receptors in the central nervous system of rat: a
dose-response study. *J Toxicol Environ Health A*. 2000;61:695-707.

270\. Lallement G, Foquin A, Baubichon D, Burckhart MF, Carpentier P,
Canini F. Heat stress, even extreme, does not induce penetration of
pyridostigmine into the brain of guinea pigs. *Neurotoxicology*.
1998;19:759-66.

271\. Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur-Kaspa I.
Pyridostigmine brain penetration under stress enhances neuronal
excitability and induces early immediate transcriptional response. *Nat
Med*. 1996;2:1382-5.

272\. Tian H, Song X, Bressler J, Pruett S, Pope CN. Neither forced
running nor forced swimming affect acute pyridostigmine toxicity or
brain-regional cholinesterase inhibition in rats. *Toxicology*.
2002;176:39-50.

273\. Cook WO, Beasley VR, Dahlem AM, Dellinger JA, Harlin KS,
Carmichael WW. Comparison of effects of anatoxin-a(s) and paraoxon,
physostigmine and pyridostigmine on mouse brain cholinesterase activity.
*Toxicon*. 1988;26:750-3.

274\. Lin J, Freeman JJ, Kosh JW. Antagonism of acute physostigmine and
neostigmine toxicity in mice by hemicholinium-3. *Res Commun Chem Pathol
Pharmacol*. 1987;56:137-40.

275\. Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N.
Effects of coenzyme Q10 on exercise tolerance in chronic stable angina
pectoris. *Am J Cardiol*. 1985;56:247-51.

276\. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S.
Coenzyme Q10 in health and disease. *Eur J Clin Nutr*. 1999;53:764-70.

277\. Thorsteinsdottir B, Rafnsdottir S, Geirsson AJ, Sigurjonsson SV,
Kjeld M. No difference in ubiquinone concentration of muscles and blood
in fibromyalgia patients and healthy controls. *Clin Exp Rheumatol*.
1998;16:513-4.

278\. Lister RE. An open, pilot study to evaluate the potential benefits
of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia
syndrome. *J Int Med Res*. 2002;30:195-9.

279\. Sneed PA. Treatment of fibromyalgia with ubiquinone 10 and
succinic acid. *Official Gazette of the United States Patent and
Trademark Office Patents*. 2002;1255:No Pagination.

280\. Krieger AC, Redeker NS. Obstructive sleep apnea syndrome: its
relationship with hypertension. *J Cardiovasc Nurs*. 2002;17:1-11.

281\. Blankfield RP, Zyzanski SJ. Bilateral leg edema, pulmonary
hypertension, and obstructive sleep apnea: a cross-sectional study. *J
Fam Pract*. 2002;51:561-4.

282\. Yamakawa H, Shiomi T, Sasanabe R, et al. Pulmonary hypertension in
patients with severe obstructive sleep apnea. *Psychiatry Clin
Neurosci*. 2002;56:311-2.

283\. Lee AG, Golnik K, Kardon R, Wall M, Eggenberger E, Yedavally S.
Sleep apnea and intracranial hypertension in men. *Ophthalmology*.
2002;109:482-5.

284\. Blankfield RP, Tapolyai AA, Zyzanski SJ. Left ventricular
dysfunction, pulmonary hypertension, obesity, and sleep apnea. *Sleep
Breath*. 2001;5:57-62.

285\. Silverberg DS, Iaina A, Oksenberg A. Treating obstructive sleep
apnea improves essential hypertension and quality of life. *Am Fam
Physician*. 2002;65:229-36.

286\. Chaska BW. Obstructive sleep apnea and essential hypertension\--is
there a link? *Am Fam Physician*. 2002;65:182, 185-6.

287\. Alchanatis M, Tourkohoriti G, Kakouros S, Kosmas E, Podaras S,
Jordanoglou JB. Daytime pulmonary hypertension in patients with
obstructive sleep apnea: the effect of continuous positive airway
pressure on pulmonary hemodynamics. *Respiration*. 2001;68:566-72.

288\. Richert A, Ansarin K, Baran AS. Sleep apnea and hypertension:
pathophysiologic mechanisms. *Semin Nephrol*. 2002;22:71-7.

289\. Lavie P, Silverberg D, Oksenberg A, Hoffstein V. Obstructive sleep
apnea and hypertension: from correlative to causative relationship. *J
Clin Hypertens (Greenwich)*. 2001;3:296-301.

290\. von Kanel R, Le DT, Nelesen RA, Mills PJ, Ancoli-Israel S,
Dimsdale JE. The hypercoagulable state in sleep apnea is related to
comorbid hypertension. *J Hypertens*. 2001;19:1445-51.

291\. Sanders MH. Article reviewed: Association of sleep-disordered
breathing, sleep apnea, and hypertension in a large community-based
study. 2000;1:327-328.

292\. Otsuka K. \[Nasal CPAP treatment and hypertension and altered
cardiovascular variability associated with obstructive sleep apnea
(OSA)\]. *Nippon Rinsho*. 2001;59:983-91.

293\. Narkiewicz K, Somers VK. Obstructive sleep apnea as a cause of
neurogenic hypertension. *Curr Hypertens Rep*. 1999;1:268-73.

294\. Shiomi T, Guilleminault C, Sasanabe R, et al. Primary pulmonary
hypertension with central sleep apnea: sudden death after bilevel
positive airway pressure therapy. *Jpn Circ J*. 2000;64:723-6.

295\. Hudgel DW. Beyond systemic hypertension: understanding cardiac
dysfunction in obstructive sleep apnea. *Respiration*. 2000;67:360-1.

296\. Salo TM, Jula AM, Piha JS, et al. Comparison of autonomic
withdrawal in men with obstructive sleep apnea syndrome, systemic
hypertension, and neither condition. *Am J Cardiol*. 2000;85:232-8.

297\. Willis RA, Anthony M, Loop R, Llanes C, Folkers K. The effect of
ethanol and/or food restriction on coenzyme Q in liver in rats. *Mol
Aspects Med*. 1997;18 Suppl:S205-11.

298\. Silvestre-Aillaud P, BenDahan D, Paquis-Fluckinger V, et al. Could
coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to
3243 mutation of mtDNA? *Diabetologia*. 1995;38:1485-6.

299\. Kucharska J, Braunova Z, Ulicna O, Zlatos L, Gvozdjakova A.
Deficit of coenzyme Q in heart and liver mitochondria of rats with
streptozotocin-induced diabetes. *Physiol Res*. 2000;49:411-8.

300\. Liou CW, Huang CC, Lin TK, Tsai JL, Wei YH. Correction of
pancreatic beta-cell dysfunction with coenzyme Q(10) in a patient with
mitochondrial encephalomyopathy, lactic acidosis and stroke-like
episodes syndrome and diabetes mellitus. *Eur Neurol*. 2000;43:54-5.

301\. Kishi T, Kishi H, Watanabe T, Folkers K. Bioenergetics in clinical
medicine. XI. Studies on coenzyme Q and diabetes mellitus. *J Med*.
1976;7:307-21.

302\. Iwasaki Y, Wakata N, Kinoshita M. Parkinsonism induced by
pyridostigmine. *Acta Neurol Scand*. 1988;78:236.

303\. Iwasaki Y, Kinoshita M, Wakata N. \[A case report of
pyridostigmine induced parkinsonism\]. *Rinsho Shinkeigaku*.
1988;28:662-4.

304\. Gothoni P, Lehtinen M, Fincke M. Drugs for Parkinson\'s disease
reduce tremor induced by physostigmine. *Naunyn Schmiedebergs Arch
Pharmacol*. 1983;323:205-10.

305\. Friedrich MJ. Pesticide study aids Parkinson research. *Jama*.
1999;282:2200.

306\. Semchuk KM, Love EJ, Lee RG. Parkinson\'s disease and exposure to
agricultural work and pesticide chemicals. *Neurology*. 1992;42:1328-35.

307\. Ritz B, Yu F. Parkinson\'s disease mortality and pesticide
exposure in California 1984-1994. *Int J Epidemiol*. 2000;29:323-9.

308\. Taylor MC, Le Couteur DG, Mellick GD, Board PG. Paraoxonase
polymorphisms, pesticide exposure and Parkinson\'s disease in a
Caucasian population. *J Neural Transm*. 2000;107:979-83.

309\. Berger A. Parkinson\'s disease linked with pesticide. *Bmj*.
2000;321:1175A.

310\. Adam D. Pesticide use linked to Parkinson\'s disease. *Nature*.
2000;408:125.

311\. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV,
Greenamyre JT. Chronic systemic pesticide exposure reproduces features
of Parkinson\'s disease. *Nat Neurosci*. 2000;3:1301-6.

312\. Helmuth L. Neuroscience. Pesticide causes Parkinson\'s in rats.
*Science*. 2000;290:1068.

313\. Karen DJ, Li W, Harp PR, Gillette JS, Bloomquis JR. Striatal
dopaminergic pathways as a target for the insecticides permethrin and
chlorpyrifos. *Neurotoxicology*. 2001;22:811-7.

314\. Ambrani LM, Van Woert MH. Modification of the tremorigenic
activity of physostigmine. *Br J Pharmacol*. 1972;46:344-7.

315\. Ambani LM, Van Woert MH, Bowers MB, Jr. Physostigmine effects on
phenothiazine-induced extrapyramidal reactions. *Arch Neurol*.
1973;29:444-6.

316\. Haley RW, Hom J, Roland PS, et al. Evaluation of neurologic
function in Gulf War veterans. A blinded case-control study. *Jama*.
1997;277:223-30.

317\. Hom J, Haley RW, Kurt TL. Neuropsychological correlates of Gulf
War syndrome. *Arch Clin Neuropsychol*. 1997;12:531-544.

318\. McDowell I. Alzheimer\'s disease: insights from epidemiology.
*Aging (Milano)*. 2001;13:143-62.

319\. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR,
Markesbery WR. Linguistic ability in early life and cognitive function
and Alzheimer\'s disease in late life. Findings from the Nun Study.
*Jama*. 1996;275:528-32.

320\. Head injury linked to increased risk of Alzheimer\'s disease. *FDA
Consum*. 2001;35:8.

321\. Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury
in early adulthood and risk of Alzheimer\'s disease and other dementias.
*Neurology*. 2000;55:1158-66.

322\. SoRelle R. Head injuries linked to Alzheimer\'s disease.
*Circulation*. 2000;102:E9036-7.

323\. Sobel RK. Alzheimer\'s first blow. Head injuries raise risk. *US
News World Rep*. 2000;129:54.

324\. Norris FH, Tan Y, Fallat RJ, Elias L. Trial of oral physostigmine
in amyotrophic lateral sclerosis. *Clin Pharmacol Ther*. 1993;54:680-2.

325\. Aquilonius SM, Askmark H, Eckernas SA, et al. Cholinesterase
inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A
controlled study of physostigmine versus neostigmine. *Acta Neurol
Scand*. 1986;73:628-32.

326\. Backman SB, Stein RD, Blank DW, Collier B, Polosa C. Different
properties of the bradycardia produced by neostigmine and edrophonium in
the cat. *Can J Anaesth*. 1996;43:731-40.

327\. Baraka A. Safe reversal. 2. Atropine-neostigmine mixture: an
electrocardiographic study. *Br J Anaesth*. 1968;40:30-6.

328\. Baraka A. Safe reversal. 1. Atropine followed by neostigmine. An
electrocardiographic study. *Br J Anaesth*. 1968;40:27-9.

329\. Beebe DS, Shumway SJ, Maddock R. Sinus arrest after intravenous
neostigmine in two heart transplant recipients. *Anesth Analg*.
1994;78:779-82.

330\. Bramich NJ, Brock JA, Hirst GD. Potentiation by neostigmine of
responses to vagal nerve stimulation in the sinus venosus of the toad.
*Auton Neurosci*. 2000;82:109-14.

331\. Cavaliere F, Martinelli L, Rossi M, Zamparelli R, Gennari A,
Schiavello R. \[Effectiveness of low-dose neostigmine in the treatment
of sinus tachycardia during aortocoronary bypass\]. *Minerva
Anestesiol*. 1993;59:361-5.

332\. Constable PD, Muir WW, 3rd, Freeman L, Hoffsis GF, St Jean G,
Welker FH. Atrial fibrillation associated with neostigmine
administration in three cows. *J Am Vet Med Assoc*. 1990;196:329-32.

333\. Dowdy EG. Effect of neostigmine on cardiac rhythm in digitalized
dogs. Guest discussion. *Anesth Analg*. 1971;50:1088-9.

334\. Fuchs-Buder T, Ziegenfuss T, Lysakowski K, Tassonyi E. Antagonism
of vecuronium-induced neuromuscular block in patients pretreated with
magnesium sulphate: dose-effect relationship of neostigmine. *Br J
Anaesth*. 1999;82:61-5.

335\. Eldor J, Frankel DZ. Use of low-dose neostigmine intravenously in
the treatment of supraventricular tachycardia: an immediate bradycardic
effect. *Resuscitation*. 1989;18:103-10.

336\. Ivankovic AD, Ruggiero RP, el-Etr AA, Kaye MP. Effect of
neostigmine on cardiac rhythm in digitalized dogs. *Anesth Analg*.
1971;50:1079-88.

337\. Kadoya T, Seto A, Aoyama K, Takenaka I. Development of rapid
atrial fibrillation with a wide QRS complex after neostigmine in a
patient with intermittent Wolff-Parkinson-White syndrome. *Br J
Anaesth*. 1999;83:815-8.

338\. Kjellberg M, Tammisto T. Heart-rate changes after atropine and
neostigmine given for the reversion of muscle paralysis. *Acta
Anaesthesiol Scand*. 1970;14:203-10.

339\. Klingenmaier CH, Bullard R, Thompson D, Watson R. Reversal of
neuromuscular blockade with a mixture of neostigmine and glycopyrrolate.
*Anesth Analg*. 1972;51:468-72.

340\. Pratila MG, Pratilas V. A case of tachydysrhythmia. Refractory to
propranolol and responsive to neostigmine. *Anaesthesia*.
1977;32:1017-9.

341\. Raymond CW. Letter: Neostigmine methysulfate in the treatment of
cardiac arryhthmia induced by perphenazine-amitriptyline. *Can Med Assoc
J*. 1976;114:102-7.

342\. Rosner V, Kepes ER, Foldes FF. The effects of atropine and
neostigmine on heart rate and rhythm. Recommendation for their use to
reverse residual neuromuscular block. *Br J Anaesth*. 1971;43:1066-74.

343\. Schultheis LW, Balser JR, Calkins H, et al. High dose neostigmine
treatment of malignant sinus tachycardia. *Pacing Clin Electrophysiol*.
1997;20:1369-72.

344\. Tetzlaff JE, Choban MJ. Asystole following neostigmine
administration during carotid sinus stimulation. *J Clin Anesth*.
1990;2:212-3.

345\. Wetterslev J, Jarnvig I, Jorgensen LN, Olsen NV. Split-dose
atropine versus glycopyrrolate with neostigmine for reversal of
gallamine-induced neuromuscular blockade. *Acta Anaesthesiol Scand*.
1991;35:398-401.

346\. Bigger JT, Jr., Kantor SJ, Glassman AH, Perel JM. Is physostigmine
effective for cardiac toxicity of tricyclic antidepressant drugs.
*Jama*. 1977;237:1311.

347\. Das PK, Bhattacharya SK. Studies on the effect of physostigmine on
experimental cardiac arrhythmias in dogs. *Br J Pharmacol*.
1972;44:397-403.

348\. Dysken MW, Janowsky DS. Dose-related physostigmine-induced
ventricular arrhythmia: case report. *J Clin Psychiatry*. 1985;46:446-7.

349\. Elonen E. Effect of beta-adrenoceptor blocking drugs,
physostigmine, and atropine on the toxicity of doxepin in mice. *Med
Biol*. 1975;53:231-7.

350\. Goldberger AL, Curtis GP. Immediate effects of physostigmine on
amitryptyline-induced QRS prolongation. *J Toxicol Clin Toxicol*.
1982;19:445-54.

351\. James TN, Urthaler F, Lewis RK. Termination of \"ventricular\"
arrhythmias from digoxin by selective production of complete
atrioventricular block with physostigmine in the dog. *J Pharmacol Exp
Ther*. 1979;211:561-70.

352\. Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M. Effects of
physostigmine on pulse, blood pressure, and serum epinephrine levels.
*Am J Psychiatry*. 1985;142:738-40.

353\. Kulig K, Rumack BH. Physostigmine and asystole. *Ann Emerg Med*.
1981;10:228-20.

354\. Maister AH. Atrial fibrillation following physostigmine. *Can
Anaesth Soc J*. 1983;30:419-21.

355\. Pentel P, Peterson CD. Asystole complicating physostigmine
treatment of tricyclic antidepressant overdose. *Ann Emerg Med*.
1980;9:588-90.

356\. Schmidt W, Lang K. Life-threatening dysrhythmias in severe
thioridazine poisoning treated with physostigmine and transient atrial
pacing. *Crit Care Med*. 1997;25:1925-30.

357\. Schulz M, Schmoldt A. Successful physostigmine treatment of acute
dothiepin intoxication. *Pharmazie*. 1994;49:614.

358\. Seitz R, Wehr M, Pallmert N. \[Arrhythmias in poisoning with
tricyclic antidepressive agents. Successful treatment with physostigmine
and sodium\]. *Dtsch Med Wochenschr*. 1982;107:1096-9.

359\. Snyder BD, Blonde L, McWhirter WR. Reversal of amitriptyline
intoxication by physostigmine. *Jama*. 1974;230:1433-4.

360\. Tobis J, Das BN. Cardiac complications in amitriptyline poisoning.
Successful treatment with physostigmine. *Jama*. 1976;235:1474-6.

361\. Wright SP. Usefulness of physostigmine in imipramine poisoning. A
dramatic response in a child resistant to other therapy. *Clin Pediatr
(Phila)*. 1976;15:1123-8.

362\. Weisdorf D, Kramer J, Goldbarg A, Klawans HL. Physostigmine for
cardiac and neurologic manifestations of phenothiazine poisoning. *Clin
Pharmacol Ther*. 1978;24:663-7.

363\. Dorner G, Staudt J, Wenzel J, Kvetnansky R, Murgas K. Further
evidence of teratogenic effects apparently produced by neurotransmitters
during brain differentiation. *Endokrinologie*. 1977;70:S326-330.

364\. Dorner G, Hecht K, Hinz G. Teratopsychogenetic effects apparently
produced by nonphysiological neurotransmitter concentrations during
brain differentiation. *Endokrinologie*. 1976;68:1-5.

365\. Dorner G, Hinz G. Apparent effects of neurotransmitters on sexual
differentiation of the brain without mediation of sex hormones.
*Endokrinologie*. 1978;71:S104-108.

366\. Landauer W. Cholinomimetic teratogens: Studies with chicken
embryos. *Teratology*. 1975;12:125-146.

367\. Al-Shekhlee A, Robin N, Kaminski HJ. Pyridostigmine-induced
microcephaly. *Neurology*. 2001;56:1606-7.

368\. Cowan DN, DeFraites RF, Gray GC, Goldenbaum MB, Wishik SM. The
risk of birth defects among children of Persian Gulf War veterans. *N
Engl J Med*. 1997;336:1650-6.

369\. Penman AD, Tarver RS, Currier MM. No evidence of increase in birth
defects and health problems among children born to Persian Gulf War
Veterans in Mississippi. *Mil Med*. 1996;161:1-6.

370\. Araneta MR, Destiche DA, Schlangen KM, Merz RD, Forrester MB, Gray
GC. Birth defects prevalence among infants of Persian Gulf War veterans
born in Hawaii, 1989-1993. *Teratology*. 2000;62:195-204.

371\. Doyle P, Roman E, Maconochie N. Birth defects among children of
Persian Gulf War veterans. *N Engl J Med*. 1997;337:1175-6.

372\. Zhou YX, Yan QJ, Ci YX, et al. Detection of the organophosphorus
nerve agent sarin by a competitive inhibition enzyme immunoassay. *Arch
Toxicol*. 1995;69:644-8.

372.5 Kang H, Magee C, Mahan C, et al. Pregnancy outcomes among U.S.
Gulf War veterans: a population-based survey of 30,000 veterans. *Ann
Epidemiol*. 2001;11:504-11.